LEXEO Therapeutics Closes $100 Million Series B Financing to Advance Clinical Stage Gene Therapy Pipeline and Enhance Preclinical Footprint

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3E1wxht
via IFTTT